(377) Optimization of the Medical Protocol for the Treatment of Peyronie's Disease
Abstract
Peyronie's disease is a widespread and potentially disabling condition affecting patients’ quality of life. Practitioners and researchers should explore the different approaches proposed to optimize management and tailor it to the patient.
To evaluate the efficacy and reproducibility of a semi-invasive protocol for Peyronie's disease made of "optimized" platelet-rich plasma (PRP) injections + penile traction + Phosphodiesterase type 5 (PDE5) inhibitors.
The study selected 12 patients who presented with the typical symptomatology of Peyronie's disease for less than 18 months with a curvature of less than 60° and had not received any other medical therapy. The average age was 49 years. 8 patients had a single plaque while 4 had multiple locations. The protocol consisted of 6 sessions of PRP injection, associated with a stretching of the penis and a daily intake of 5mg of Tadalafil. The parameters collected before and after the protocol were: Angulation of the penis, pain Visual Analogue Scale (VAS) on intercourse, International Index of the erectile function-5items (IIEF5), plaque size on ultrasound as well as the Peyronie Disease's Questionnaire scale (PDQ). Protocol description: - PRP injections: 6 injection sessions at one-week intervals. Each session is performed as follows: 1) Autologous collection of 10ml of blood which will be centrifuged at a force of 1500g RCF for 10min, only the supernatant plasma will be taken, avoiding the buffy coat which will only maintain an…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.